CORGENTECH FILES IND APPLICATION TO BEGIN PHASE I/II TRIAL OF NEW DRUG CANDIDATE FOR ECZEMA

Corgentech has filed an investigational new drug application with the FDA to begin a Phase I/II clinical trial of its NF-kappaB Decoy (NF-kB Decoy) drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema.

This is the first of two Phase I/II trials to be initiated. The second trial will be conducted in Europe and is expected to be initiated in the first half of 2005 in a similar patient population. The multicenter, randomized, double-blind, dose-ranging trial will evaluate the safety and feasibility of repeated application of three concentrations of NF-kB Decoy in adult patients with mild-to-moderate eczema.